Fortrea (NASDAQ:FTRE) just dropped a mic-worthy Q3 earnings report, and investors went wild, pushing the stock up a staggering 37% today. The company, a global contract research organization, posted $674.9 million in revenue and a solid adjusted EBITDA of $64.2 million, marking a 16.3% sequential jump. CEO Tom Pike didn't hold back, spotlighting Fortrea's smooth post-spin progress, with over 90% of IT infrastructure now migrated to its independent systems. Oh, and let's not forget that juicy 1.23x book-to-bill ratio, showing a pipeline packed with pharma and biotech contracts.
But here's the kicker: despite a GAAP net loss of $18.5 million, Fortrea smashed expectations with adjusted EPS of $0.23. Their backlog? A beastly $7.57 billion. Management is standing tall, reaffirming its full-year revenue guidance at $2.7 to $2.725 billion. It's clearthey're laser-focused on delivering, even with some hurdles in their rearview mirror.
For savvy investors, today's stock rally screams one thing: confidence. Fortrea is proving it's got what it takes to dominate the CRO space and drive real healthcare innovation. With a robust backlog and momentum building, the big question is whether this breakout moment is just the beginning of a much bigger run. Eyes on Q4it's going to be a show
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.